Xpert NPM1 Mutation provides the percent ratio of mutant NPM1 to ABL1 endogenous control mRNA transcripts. Credit: Cepheid / PRNewswire.

US-based molecular diagnostics company Cepheid has secured the CE mark for its molecular in vitro diagnostic test, Xpert NPM1 Mutation.

The test is intended to quantify mutant NPM1 mRNA transcripts (types A, B and D in exon 12) in peripheral blood specimens from acute myeloid leukaemia (AML) patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Using automated real-time reverse transcription polymerase chain reaction, the test offers the per cent ratio of mutant NPM1 to ABL1 endogenous control mRNA transcripts.

Cepheid oncology medical and scientific affairs vice-president Dr Michael Bates said: “NPM1 mutations are found in approximately one-third of acute myeloid leukaemia cases and can be used to monitor response to therapy as well as to predict relapse.

“The Xpert NPM1 Mutation test quantifies the mRNA transcripts of the A, B and D mutations accounting for approximately 90% of NPM1 mutant cases, plus the ABL control gene and provides an easy and convenient method of assessing response to therapy and improving the management of patients with AML.”

As part of minimal residual disease monitoring for AML patients with NPM1 mutations, the European LeukemiaNet advises the utilisation of quantitative molecular assessment of NPM1 through qPCR.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new diagnostic test is said to complement the company’s haematology-oncology portfolio, which comprises Xpert BCR-ABL Ultra p190 and Xpert BCR-ABL Ultra.

In February this year, Cepheid received emergency use authorisation (EUA) from the US Food and Drug Administration for its Xpert Mpox test.

As part of the EUA, Xpert Mpox is now authorised for use in point-of-care settings on the GeneXpert Xpress systems.